Skip to content

Trial Summary

This phase III trial is comparing the safety and effectiveness of a hormone therapy drug called Giredestrant with other types of hormone therapy for the treatment of stage 1-3 ER positive and HER2 negative breast cancer.

Acronym:

lidERA

ACTRN/NCT /ethics:

NCT04961996

Scientific title:

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

Sponsor / Cooperative group:

Hoffmann-La Roche

Trial & Patient Characteristics

Cancer TypeBreast
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2021-08-27
Anticipated End Date2025-12-19

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Kerry Cheong
Recruitment StatusRecruiting